Ro Review: GLP-1 Telehealth Evidence & Costs

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ro is a direct-to-consumer telehealth platform that began operations in 2019 and has expanded significantly in weight management and metabolic health. The platform reported serving over 1 million patients by 2024, primarily through telehealth consultations and prescription fulfillment for medications including GLP-1 receptor agonists.

Patients researching telehealth GLP-1 options often encounter Ro's name prominently. Understanding Ro's clinical model, cost structure, and evidence base is essential for informed decision-making. PlexusDx takes a precision-wellness approach, offering compounded GLP-1 medications from licensed 503A pharmacies alongside optional genetic testing to support more personalized provider conversations.

What Ro Offers and How Its Telehealth Model Works

Ro provides virtual consultations with licensed healthcare providers, assessment questionnaires, and home delivery of prescribed medications. Patients complete an online evaluation; providers review medical history and vital data before prescribing. Ro charges consultation fees ranging from $99 to $199, plus medication costs billed directly to patients or insurance.

Ro's proprietary platform integrates telehealth coordination with pharmacy fulfillment. The company partnered with external pharmacies and later developed in-house fulfillment capabilities. Ro focuses on convenience and accessibility, positioning telehealth as a lower-friction entry point for GLP-1 therapy compared to traditional office-based care.

Clinical Evidence Base and Provider Oversight at Ro

Ro's clinical model relies on published GLP-1 trial data (including STEP and SELECT trials) to inform provider protocols. Providers follow evidence-based screening for contraindications, cardiovascular risk, and renal function. Ro does not conduct proprietary clinical trials but aligns recommendations with FDA-approved indications and published guidelines.

Provider credentials at Ro include licensed physicians, nurse practitioners, and physician assistants. Patients interact with licensed clinicians; however, continuity of care may vary because appointments are not always with the same provider. Ro's model prioritizes initial access over long-term relationship-based care, reflecting the asynchronous telehealth model.

Ro Pricing, Insurance, and Out-of-Pocket Costs

Ro's consultation fees start at $99 and medications typically range from $150 to $400 per month depending on dose and specific GLP-1 (semaglutide vs. tirzepatide). Ro accepts some insurance plans, though coverage varies by state and employer. Many patients pay out-of-pocket; Ro offers subscription discounts for prepaid bundles.

Patients should verify whether their insurance accepts Ro's in-network status and whether GLP-1 is covered for their diagnosis (weight loss vs. diabetes). Prior authorization and step-therapy requirements differ by plan. Ro provides cost transparency tools but final out-of-pocket costs depend on individual policy terms.

Telehealth GLP-1 Provider Comparison Framework

Many direct-to-consumer telehealth platforms (Ro, Calibrate, Noom, Devoted Health, Amazon Pharmacy, and others) now offer GLP-1. Each differs in provider continuity, compounding options, genetic testing availability, and cost structures. Understanding these dimensions helps patients select the model that aligns with their clinical needs and preferences.

Factor	Ro	Compounded via 503A Pharmacy	PlexusDx Model
Medication Source	Branded/in-house pharmacy	Licensed compounding pharmacy	Licensed 503A compounding only
Consultation Model	Asynchronous telehealth, variable provider continuity	Provider directed, continuity varies	Precision-focused with genetic context
Genetic Testing	Not routinely offered	Not typically included	Precision Peptide Genetic Test available
Cost Range (Monthly)	$150–$400 + $99–$199 consultation	$150–$400	$249 compounded; $99 genetic test add-on
Insurance Integration	Partial; state and plan dependent	Case-by-case	Billed separately; 503A pharmacies handle insurance

Genetic Predisposition Insights and Peptide Pathway Context

GLP-1 response varies significantly between individuals. Genetic variants in pathways controlling appetite, glucose regulation, and metabolic rate (such as GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609) may influence how a person's body responds to GLP-1 therapy. These predispositions do not determine outcomes but may provide context for clinical decision-making.

Ro's standard assessment does not include genetic testing for peptide pathways. Patients relying solely on clinical questionnaires may miss insights into their metabolic biology that could inform personalized treatment conversations. Genetic testing is an optional tool—not a replacement for provider evaluation—that can support more informed discussions about medication selection and dosing strategy.

Safety Screening and Medical Eligibility at Ro

Ro screens for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe kidney disease, and uncontrolled hypertension. Providers review medication interactions and assess cardiovascular risk. However, asynchronous telehealth may not capture nuanced clinical context that emerges in longitudinal office visits.

Patients with complex comorbidities, polypharmacy, or unclear medical histories may benefit from in-person evaluation before telehealth GLP-1 initiation. Ro provides a reasonable pathway for straightforward cases; patients with high clinical complexity should discuss their full history with a qualified provider, whether via Ro or another platform, to ensure safety.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded semaglutide and tirzepatide from licensed 503A pharmacies, providing a compounded-only alternative to branded GLP-1 medications. Compounded formulations may appeal to patients seeking cost optimization or those who prefer pharmacy flexibility. Compounded GLP-1 agents are not FDA-approved but are synthesized under USP standards by licensed compounding pharmacies.

PlexusDx offers the Precision Peptide Genetic Test ($99 as an add-on or $298 standalone) to assess predispositions in peptide pathway variants. This test may help provide context about genetic factors influencing GLP-1 response pathways—such as GLP1R, GIPR, FTO, and MC4R variants. The test results are not predictive of exact medication response and should be interpreted with a qualified healthcare provider as one input into personalized treatment conversations.

Patients considering Ro or other telehealth platforms may benefit from a more detailed genetic and biomarker assessment before starting GLP-1 therapy. Discussing genetic predispositions alongside clinical history, vital signs, and lab work can support a more personalized approach to medication selection and dosing. PlexusDx providers can integrate genetic insights into ongoing treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How does Ro's telehealth model differ from traditional office-based GLP-1 prescribing?

Ro uses asynchronous virtual consultations with variable provider continuity; patients do not typically maintain an ongoing relationship with the same clinician. Traditional office visits allow for longitudinal relationships, in-person physical exams, and nuanced clinical discussion. Both models can be appropriate depending on clinical complexit...

Is Ro covered by insurance?

Ro partners with select insurance plans but coverage varies by state and employer. Many patients pay out-of-pocket. Patients should verify their plan's GLP-1 coverage and whether Ro participates in their network before enrolling.

Does Ro offer genetic testing for GLP-1 response?

Ro does not routinely include genetic testing in its standard assessment. PlexusDx offers the Precision Peptide Genetic Test to assess peptide pathway predispositions, providing additional context for personalized provider conversations beyond typical telehealth questionnaires.

Can genetic testing predict how well I'll respond to GLP-1?

Genetic testing reveals predispositions in peptide pathway variants, not exact medication response. Response depends on genetics, lifestyle, adherence, and other clinical factors. Results should be interpreted with a qualified healthcare provider as one part of personalized treatment planning, not as a guarantee of outcomes.

What safety screening does Ro perform before prescribing GLP-1?

Ro screens for contraindications including thyroid cancer history, kidney disease, and cardiovascular risk. However, asynchronous telehealth may not capture all clinical nuances. Patients with complex medical histories should ensure their full health picture is reviewed by a qualified provider before initiating GLP-1.

How does PlexusDx compounded GLP-1 differ from Ro's offerings?

PlexusDx provides compounded GLP-1 medications (semaglutide and tirzepatide) from licensed 503A pharmacies, with optional Precision Peptide Genetic Testing. Compounded formulations offer pharmacy flexibility and cost alternatives. PlexusDx does not offer branded medications; Ro may include branded or in-house formulations depending on availability.

Ro Review: Clinical Evidence, Cost Analysis, and Personalized GLP-1 Options